Literature DB >> 20049501

Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity.

Hui Li1, Wuqi Song, Yang Li, Yanhong Liu, Jing Bai, Xiu Li, Fengyun Mu, Yao Wang, Fengshan Zhang, Liju Su, Fengmin Zhang.   

Abstract

This study was to evaluate the diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in northern Chinese Han patients with rheumatoid arthritis (RA) and its correlation with disease activity. Clinical data and serum samples were collected from 112 RA patients and 55 non-RA patients. Statistical analyses of the correlations among anti-CCP antibodies, other serological markers, and the RA patients' clinical characteristics were performed using SPSS 11.5 software. Anti-CCP antibodies were detected in 77.7% of all RA patients and 80.4% of the RA patients with a disease duration of 3 years or less. The combined diagnosis using high titer anti-CCP antibodies (>or=100 RU/ml) with a concomitant positive rheumatoid factor (RF) test exhibited the greatest diagnostic specificity; it achieved 87.9% for all RA patients and 90.1% for the patients with disease duration of three years or less. Moreover, anti-CCP antibodies showed medium correlations to the RA patient's serum RF titer (r = 0.560, P < 0.001) and disease activity (DAS28 score; r = 0.404, P < 0.001). Compared with the patients with low anti-CCP antibody titers (<100 RU/ml), patients with high anti-CCP antibody titers showed higher RF titers, worse DAS28 scores, and severe morning stiffness (P < 0.01). This study suggests that anti-CCP antibodies can be used for RA diagnosis and disease activity evaluation for northern Han Chinese patients. A combined diagnosis using both high titers of anti-CCP antibodies (>or=100 RU/ml) and a positive RF test markedly improves RA diagnostic specificity. Patients' DAS28 scores rise and morning stiffness intensifies with increasing anti-CCP antibody titers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20049501     DOI: 10.1007/s10067-009-1337-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF.

Authors:  I G Silveira; R W Burlingame; C A von Mühlen; A L Bender; H L Staub
Journal:  Clin Rheumatol       Date:  2007-04-05       Impact factor: 2.980

2.  Association between the serotonin 1A receptor C(-1019)G polymorphism and major depressive disorder in the northern Han ethnic group in China.

Authors:  Ying Wu; Yong Xu; Yan Sun; Yan-fang Wang; Xia Li; Xiao-e Lang; Wei-ping Wang; Ke-rang Zhang
Journal:  Chin Med J (Engl)       Date:  2008-05-20       Impact factor: 2.628

3.  Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  R Mediwake; D A Isenberg; G A Schellekens; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 4.  Clinical significance of anti-CCP antibodies in rheumatoid arthritis.

Authors:  Tsuneyo Mimori
Journal:  Intern Med       Date:  2005-11       Impact factor: 1.271

5.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.

Authors:  Floris A van Gaalen; Jill van Aken; Tom W J Huizinga; Geziena M Th Schreuder; Ferdinand C Breedveld; Eric Zanelli; Walther J van Venrooij; Cornelis L Verweij; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2004-07

6.  Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.

Authors:  Xiaofeng Zeng; Maixing Ai; Xinping Tian; Xiaodan Gan; Yanping Shi; Qinfang Song; Fulin Tang
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

7.  The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.

Authors:  Y Xue; J Zhang; Y-M Chen; M Guan; S G Zheng; H-J Zou
Journal:  Scand J Rheumatol       Date:  2008 May-Jun       Impact factor: 3.641

8.  [Association of the PADI4 gene polymorphism and HLA-DRB1 shared epitope alleles with rheumatoid arthritis].

Authors:  Lie-ying Fan; Ming Zong; Tian-bao Lu; Lin Yang; Yuan-yuan Ding; Jian-wei Ma
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2009-02

9.  The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register.

Authors:  M Bukhari; W Thomson; H Naseem; D Bunn; A Silman; D Symmons; A Barton
Journal:  Arthritis Rheum       Date:  2007-09

10.  New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples.

Authors:  Thomas Barnetche; Arnaud Constantin; Alain Cantagrel; Anne Cambon-Thomsen; Pierre-Antoine Gourraud
Journal:  Arthritis Res Ther       Date:  2008-02-28       Impact factor: 5.156

View more
  9 in total

1.  MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.

Authors:  Xiaoxia Yu; Lei Zhang; Lixin Wang; Weiwei Lu; Fengyan Sun; Ping Xu; Guobin Lan
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

2.  Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Ajchara Koolvisoot; Emvalee Aromdee; Praveena Chiowchanwesawakit; Chayawee Muengchan
Journal:  Rheumatol Int       Date:  2015-04-23       Impact factor: 2.631

3.  Discriminative and diagnostic value of anti-cyclic citrullinated peptide antibodies in Iranian patients with rheumatoid arthritis.

Authors:  Jamileh Moghimi; Raheb Ghorbani; Farnaz Hasani; Mehrdad Sheikhvatan
Journal:  Rheumatol Int       Date:  2012-04-03       Impact factor: 2.631

Review 4.  Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis in a Chinese population: a meta-analysis.

Authors:  Fei Gao; Lei Ren; Cai-Qin Zhang; Feng-Yun Mu; Yan-Qiu You; Yan-Hong Liu
Journal:  Rheumatol Int       Date:  2011-09-30       Impact factor: 2.631

5.  A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients.

Authors:  Yan Geng; Wei Zhou; Zhuo-Li Zhang
Journal:  Rheumatol Int       Date:  2011-12-24       Impact factor: 2.631

Review 6.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

7.  Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis.

Authors:  Asrul Abdul Wahab; Marlyn Mohammad; M M Rahman; Mohd Shahrir Mohamed Said
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

8.  A chronic model of arthritis supported by a strain-specific periarticular lymph node in BALB/c mice.

Authors:  Uta Baddack; Sven Hartmann; Holger Bang; Jenny Grobe; Christoph Loddenkemper; Martin Lipp; Gerd Müller
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Differential diagnosis of systemic lupus erythematosus and rheumatoid arthritis with complements C3 and C4 and C-reactive protein.

Authors:  Wenhui Li; Hui Li; Wuqi Song; Yunlong Hu; Yanhong Liu; Rong DA; Xiaobei Chen; Yang Li; Hong Ling; Zhaohua Zhong; Fengmin Zhang
Journal:  Exp Ther Med       Date:  2013-09-17       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.